Volume 1, Issue 1, Pages 1-9 (January 2019)

Slides:

Advertisements

Similar presentations

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for.

Advertisements

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Prognostic Importance of Physical Examination for.

Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Peter K. Smith, MD, Robert M. Califf, MD, Robert H

Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience John J. Sim, MD, Joel Handler, MD, Steven.

Copyright © 2015 American Medical Association. All rights reserved.

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Rethinking Cocaine-Associated Chest Pain and Acute Coronary Syndromes

Diabetes and Pregnancy

Isolated Systolic Hypertension: An Update After SPRINT

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Volume 84, Issue 2, Pages (August 2013)

Development of Clinical Practice Guidelines in the Care of People With Kidney Disease: Core Curriculum 2016 Angela C. Webster, PhD, Evi V. Nagler, MD,

Manuel Caceres, MD, Darryl S. Weiman, MD, JD

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Innovative Informatics Approaches for Peripheral Artery Disease: Current State and Provider Survey of Strategies for Improving Guideline-Based Care Alisha.

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Trends in isolated coronary artery bypass grafting: An analysis of the Society of Thoracic Surgeons adult cardiac surgery database Andrew W. ElBardissi,

Step Care Therapy for Hypertension in Diabetic Patients

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Fred H. Edwards, MD, David M. Shahian, MD, Maria V

Membranous nephropathy: When and how to treat

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies Hisato Takagi,

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

A randomized controlled trial of a web-based education intervention for women with gestational diabetes mellitus Mary Carolan-Olah, Padaphet Sayakhot

Prehypertension and chronic kidney disease: the ox or the plow?

Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from.

Characteristics of Contemporary Patients Discharged From the Hospital After an Acute Coronary Syndrome Robert J. Goldberg, PhD, Jane S. Saczynski, PhD,

Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy Eric J. Velazquez, MD,

Propofol as a panacea for acute kidney injury?

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Defining operative mortality: Impact on outcome reporting

Why surgery won the SYNTAX trial and why it matters

Zhe Zheng, MD, PhD, Heng Zhang, MD, PhD, Bo Xu, MBBS

Michael E. Halkos, MD, MSc, Henry A

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Multilevel data analysis: What? Why? How?

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Off-pump versus on-pump coronary artery bypass grafting: Insights from the Arterial Revascularization Trial Umberto Benedetto, MD, PhD, Douglas G. Altman,

Meeting AHA/ACC secondary prevention goals in a vascular surgery practice: An opportunity we cannot afford to miss Daniel Kinikini, MD, Mark R. Sarfati,

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact Jack V. Tu, MD, PhD, Anam M. Khan,

Volume 1, Issue 1, Pages (January 2019)

For everything there is a season

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Peter K. Smith, MD, Robert M. Califf, MD, Robert H

Sara L. Zettervall, MD, MPH, Dominique B. Buck, MD, Peter A

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

The future of renoprotection: Frustration and promises

Isolated Systolic Hypertension: An Update After SPRINT

Rethinking Cocaine-Associated Chest Pain and Acute Coronary Syndromes

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

Volume 64, Issue 2, Pages (August 2003)

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Volume 73, Issue 5, Pages (March 2008)

CLINICAL OUTCOMES OF TREATMENT BY PERCUTANEOUS CORONARY INTERVENTION VERSUS CORONARY ARTERY BYPASS GRAFT SURGERY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Volume 81, Issue 11, Pages (June 2012)

Friends, social networks, and progressive chronic kidney disease

Optimization of pre-ESRD care: The key to improved dialysis outcomes

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy Andrea M. Steely, MD, Peter W.

Presentation transcript:

Volume 1, Issue 1, Pages 1-9 (January 2019) Measuring Cardiovascular Quality in Primary Care Using Canadian Cardiovascular Harmonization of National Guidelines Endeavour and Electronic Medical Record Data in Ontario Theresa M. Lee, MHI, BA&Sc, Sheldon W. Tobe, MD, MScCH (HPTE), Debra A. Butt, MD, MSc, Noah M. Ivers, MD, PhD, Liisa Jaakkimainen, MD, MSc, Peter Liu, MD, Kimberly Walker, MPH, Karen Tu, MD, MSc CJC Open Volume 1, Issue 1, Pages 1-9 (January 2019) DOI: 10.1016/j.cjco.2018.11.003 Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions

Figure 1 Adherence to Canadian Cardiovascular Harmonization of National Guidelines Endeavour (C-CHANGE) quality indicators (QIs) in the Electronic Medical Record Administrative Data Linked Database (EMRALD) population. 2hPG, 2-hour plasma glucose; A1c, haemoglobin A1c; ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; ECG, electrocardiogram; EMR, electronic medical record; FPG, fasting plasma glucose; HIV, human immunodeficiency virus; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; PCI, percutaneous coronary intervention; PO, per os (by mouth); SBP, systolic BP. ∗Denotes the QI is an outcome-based indicator (QI 2, 11, 12, 14). The remaining indicators are process-based indicators. CJC Open 2019 1, 1-9DOI: (10.1016/j.cjco.2018.11.003) Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions

Figure 1 Adherence to Canadian Cardiovascular Harmonization of National Guidelines Endeavour (C-CHANGE) quality indicators (QIs) in the Electronic Medical Record Administrative Data Linked Database (EMRALD) population. 2hPG, 2-hour plasma glucose; A1c, haemoglobin A1c; ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; ECG, electrocardiogram; EMR, electronic medical record; FPG, fasting plasma glucose; HIV, human immunodeficiency virus; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; PCI, percutaneous coronary intervention; PO, per os (by mouth); SBP, systolic BP. ∗Denotes the QI is an outcome-based indicator (QI 2, 11, 12, 14). The remaining indicators are process-based indicators. CJC Open 2019 1, 1-9DOI: (10.1016/j.cjco.2018.11.003) Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions